HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $80.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 186.02% from the company's current price.

Other equities analysts have also issued research reports about the company. Citigroup initiated coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price target for the company. Wolfe Research lowered Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Finally, Wells Fargo & Company upgraded Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 26th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 3.8 %

CLDX stock traded up $1.02 during trading hours on Monday, hitting $27.97. 1,152,406 shares of the stock traded hands, compared to its average volume of 853,341. The stock has a 50-day simple moving average of $35.82 and a 200 day simple moving average of $36.66. Celldex Therapeutics has a one year low of $22.11 and a one year high of $53.18. The company has a market cap of $1.85 billion, a P/E ratio of -10.13 and a beta of 1.55.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The business had revenue of $2.50 million during the quarter, compared to analysts' expectations of $1.13 million. Analysts forecast that Celldex Therapeutics will post -2.5 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CLDX. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics in the 2nd quarter valued at approximately $76,000. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics in the 1st quarter valued at approximately $147,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company's stock valued at $192,000 after acquiring an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Quest Partners LLC raised its stake in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 6,879 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.